ARBIDOL is the direct acting antiviral agent. ARBIDOL is approved for treatment and prevention of cold and flu in Russia. ARBIDOL action is clinically proven for a broad spectrum of antiviral activity, against influenza A and B.
During joint studies of Russian and foreign scientists it was proved that ARBIDOL possessed a unique action mechanism, i.e. blocking of influenza virus hemagglutinin and inhibition of fusion process.
ARBIDOL blocks early stage of virus replication, prevents virus penetration into the cell due to the blocking of virus fusion with the cell membrane.
Fusion mechanism is the universal mechanism of multiple viruses' penetration in to the cells. That is why ARBIDOL has a wide spectrum of antiviral activity.
ARBIDOL acts on various ARVI agents, it is active with respect to the viruses of influenza A and B, rhinovirus, corona virus, respiratory syncytial virus, rotavirus and also the number of other viruses, i.e. agents of respiratory infections.
In 2013, ARBIDOL was included in the WHO Anatomical Therapeutic Chemical Classification System and assigned the International ATC code as a direct acting antiviral medicinal product (J05A - Direct acting antivirals).
The International Society for Influenza and other Respiratory Virus Diseases (isirv) included ARBIDOL in the list of Influenza Antivirals as an inhibitor of the membrane fusion activity of the hemagglutinin, which represents a fourth class of antivirals licensed for prophylaxis and treatment of influenza.
Active substances. Umifenovirum. АТC Code: J05AX13. INN: Umifenovirum. Pharmacotherapeutic group: antiviral agent. Pharmacodynamics. Arbidol is the antiviral medicinal product. It specifically inhibits in vitro viruses of influenza A and B and other viruses, i.e. agents of Acute Respiratory Virus Infections (ARVI). Based on its antiviral activity mechanism it belongs to the fusion inhibitors (fusions); it interacts with virus hemagglutinin. Contraindications. Hypersensitivity to Umifenovirum or any other component of the medicinal product; Paediatric patients under 2 years old. First trimester of pregnancy. Breast feeding period. Adverse reactions. Rare – allergic reactions.